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THE EPIDEMIOLOGY OF VANCOMYCIN-RESISTANT
ENTEROCOCCUS COLONIZATION IN A MEDICAL
INTENSIVE CARE UNIT
David K. Warren, MD; Marin H. Kollef, MD; Sondra M. Seiler, BA; Scott K. Fridkin, MD; Victoria J. Fraser, MD
Vancomycin-resistant Enterococcus (VRE) has
become increasingly common among intensive care unit
(ICU) patients. Data from the Intensive Care
Antimicrobial Resistance Epidemiology project show that
the prevalence of vancomycin resistance among clinical
isolates of enterococci in the ICU setting was 10.4% in
1996.1 However, the true prevalence of VRE colonization
among ICU patients is higher. Previous studies, which
used active surveillance rectal cultures, reported a VRE
colonization rate between 6% and 20%2-6 among patients
admitted to the ICU and an incidence rate of becoming
colonized with VRE during ICU admission of 10% to 14%.4,6
Previous studies have also noted VRE colonization to be a
significant risk factor for developing invasive infections
with VRE among the critically ill,5,6 for whom limited treat-
ment options are available.
The Centers for Disease Control and Prevention
released recommendations for preventing the spread of
VRE within hospitals in 1995.7 These recommendations
included performing a culture survey of stools or rectal
swabs, particularly in centers with many critically ill
patients at high risk for VRE infection or colonization,
along with instituting contact precautions for colonized
patients. Despite these recommendations, the prevalence
of VRE within U.S. hospitals continues to increase.8 This
has been attributed in part to incomplete implementation
of the recommendations, along with a lack of active
screening for VRE,9 which is a labor- and resource-inten-
sive process.2,7
Previous studies have shown that “colonization
pressure” may promote VRE acquisition among critically
ill patients.10 Potentially, through the determination of
easily identifiable risk factors for VRE colonization among
newly admitted ICU patients, a strategy of selective active
surveillance of high-risk patients may become a reason-
able, cost-effective strategy for reducing colonization
pressure within the ICU. A strategy of selective active sur-
veillance for methicillin-resistant Staphylococcus aureus
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OBJECTIVE: To determine the epidemiology of colo-
nization with vancomycin-resistant Enterococcus (VRE) among
intensive care unit (ICU) patients.
DESIGN: Ten-month prospective cohort study.
SETTING: A 19-bed medical ICU of a 1,440-bed teaching
hospital.
METHODS: Patients admitted to the ICU had rectal swab
cultures for VRE on admission and weekly thereafter. VRE-posi-
tive patients were cared for using contact precautions. Clinical
data, including microbiology reports, were collected prospective-
ly during the ICU stay.
RESULTS: Of 519 patients who had admission stool cul-
tures, 127 (25%) had cultures that were positive for VRE. Risk fac-
tors for VRE colonization identified by multiple logistic regres-
sion analysis were hospital stay greater than 3 days prior to ICU
admission (adjusted odds ratio [AOR], 3.6; 95% confidence inter-
val [CI95], 2.3 to 5.7), chronic dialysis (AOR, 2.4; CI95, 1.2 to 4.5),
and having been admitted to the study hospital one to two times
(AOR, 2.3; CI95, 1.4 to 3.8) or more than two times (AOR, 6.5; CI95,
3.7 to 11.6) within the past 12 months. Of the 352 VRE-negative
patients who had one or more follow-up cultures, 74 (21%)
became VRE positive during their ICU stay (27 cases per 1,000
patient-ICU days).
CONCLUSION: The prevalence of VRE culture positivity
on ICU admission was high and a sizable fraction of ICU patients
became VRE positive during their ICU stay despite contact pre-
cautions for VRE-positive patients. This was likely due in large
part to prior VRE exposures in the rest of the hospital where
these control measures were not being used (Infect Control Hosp
Epidemiol 2003;24:257-263).
ABSTRACT
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(MRSA) among high-risk patients has been shown to
reduce the incidence of MRSA among ICU patients and to
be cost-effective.11,12
The purposes of this study were to determine the
prevalence of VRE colonization among patients admitted
to an ICU and to define risk factors for colonization, which
could potentially be used to develop a selective active sur-
veillance program. In addition, we sought to determine
the incidence of acquisition of VRE colonization among
patients admitted to the unit.
METHODS
Barnes–Jewish Hospital is a 1,440-bed, urban, ter-
tiary-care teaching hospital located in St. Louis, Missouri.
A 19-bed medical intensive care unit (MICU) was chosen
for the study. A rectal swab culture was performed on all
patients admitted to the MICU between February 14 and
December 31, 2000. If patients were admitted for more
than 48 hours, additional rectal swab cultures were per-
formed weekly and at the time of discharge from the
MICU. In addition, all clinical cultures obtained from
patients admitted for more than 48 hours were reviewed
for the occurrence of VRE. Rectal swabs were inoculated
onto bile-esculin azide agar with vancomycin at a concen-
tration of 6 g/mL. These plates were incubated at 37C
and examined at 24, 48, and 72 hours. Growth on these
plates was identified as VRE using a previously described
phenotype-based scheme for the detection and character-
ization of VRE.13 The infection control policy of the study
unit was to place patients in contact isolation, using gowns
and gloves, if they were known to be colonized with VRE
prior to ICU admission or if they had a subsequent rectal
or clinical culture positive for VRE.
Prospective data collection occurred for all patients
admitted to the MICU for more than 48 hours. Data col-
lected included demographics, medical history, admis-
sions to Barnes–Jewish Hospital within the past 12
months, hospital and ICU admission dates, Acute
Physiology and Chronic Health Evaluation II (APACHE
II) score on admission, use of vascular access catheters,
duration of mechanical ventilation, and the results of all
clinical cultures. All in-hospital antimicrobial use prior to
ICU admission was noted. For purposes of analysis,
antimicrobials were divided into anti–gram-positive,
anti–gram-negative, antianaerobic, and antifungal groups
based on the reported antimicrobial spectrum of activity.
Antimicrobial activity was expressed as categorical vari-
ables. Certain antimicrobials were classified into two or
more groups (eg, imipenem was classified as having
gram-negative, gram-positive, and anaerobic activity).
A VRE-prevalent case-patient was defined as a
patient who either was admitted with known VRE colo-
nization during the current hospitalization, or was found
to have an admission rectal culture positive for VRE, or
had VRE isolated from a clinical culture obtained within
48 hours of ICU admission. A VRE-incident case-patient
was defined as a patient with a negative admission rectal
culture and a subsequent (at least 48 hours after ICU
admission) rectal or clinical culture positive for VRE. The
incidence density for VRE acquisition was determined as
the number of VRE incident cases per 1,000 patient-days
at risk (ie, VRE-negative days).
Statistical analysis was performed using SPSS soft-
ware (version 10.0 for Windows; SPSS, Inc., Chicago, IL).
Comparisons of categorical variables were performed
using the chi-square test or Fisher’s exact test, where
appropriate. Comparisons with continuous variables were
performed using the Wilcoxon rank sum test. A P value of
less than .05 on two-tailed testing was considered signifi-
cant after the Bonferroni correction was applied to adjust
for multiple comparisons on univariate testing.
Multivariate analysis was performed using logistic regres-
sion. Variables were added to the model that were judged
a priori to be clinically relevant to avoid spurious results
with multiple comparisons.14 Whereas pre-ICU antimicro-
bial use was considered for entry into the model for VRE
colonization on admission, use of any class of antimicro-
bial was highly correlated with pre-ICU length of hospital
stay. Also, when total days of antibiotic use prior to ICU
admission was added to the model instead of pre-ICU
length of hospital stay, the resulting model was overfitted
(Hosmer and Lemeshow chi-square test, 12.7; P = .047),
without a significant change in the adjusted odds ratio of
the other predictor variables (data not shown). Therefore,
pre-ICU length of stay was used in the final model.
Multiple models were run, and the model with the highest
log likelihood value was considered the best explanatory
model. This study was approved by the Washington
University Institutional Review Board and the need for
written individual patient consent was waived.
RESULTS
During the study period, 530 patients were admitted
to the MICU and stayed longer than 48 hours. Of these,
519 (98%) had an admission surveillance swab and were
therefore eligible for study (Figure). The characteristics
of the 519 study patients are listed in Table 1. The median
age of this group was 61 years, and the mean admission
APACHE II score was 23. Within this cohort, 127 (25%) of
the patients were found to be colonized with VRE on
admission. Of these patients, only 13 (10%) subsequently
had VRE isolated in clinical cultures (1 wound and 12
urine specimens). The prevalence of VRE colonization did
not change significantly during the study period (among
the first third of patients admitted, 46 [27%] of 173 were
colonized versus 44 [25%] of the second third and 37 [21%]
of the final third; overall P = .49).
Risk factors associated with being colonized with
VRE on ICU admission are listed in Table 2. After
Bonferroni correction, a history of chronic renal failure
requiring dialysis (P < .001), a pre-ICU length of hospital
stay of 3 or more days (P < .001), one of more admissions
to the study hospital within the 12 months before the cur-
rent admission (relative risk of 2.2 for one to two admis-
sions and 3.8 for more than two admissions), and the use
of any antimicrobial prior to ICU admission were associ-
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ated with VRE colonization at the time of ICU admission.
The multivariate logistic regression analysis of factors
associated with VRE colonization at the time of ICU
admission is detailed in Table 2. Factors that were inde-
pendently associated with VRE colonization at the time of
ICU admission included having a pre-ICU length of hospi-
tal stay of 3 days or more (adjusted odds ratio [AOR], 3.6;
95% confidence interval [CI95], 2.3 to 5.7], having a histo-
ry of chronic renal failure requiring dialysis (AOR, 2.4;
CI95, 1.2 to 4.5), and having been admitted to
Barnes–Jewish Hospital one to two times (AOR, 2.3; CI95,
1.4 to 3.8) or more than two times (AOR, 6.5; CI95, 3.7 to
11.6) within the past 12 months.
The predictive power of the model for risk factors
for VRE colonization at the time of ICU admission is
detailed in Table 3. The presence of at least one of the
risk factors for VRE colonization at the time of ICU
admission had a sensitivity of 94% and a specificity of 46%,
and this was the case for 62% of the entire study popula-
tion. In this cohort, having any one of these risk factors
yielded a positive predictive value of 35% and a negative
predictive value of 93%.
Three hundred fifty two (90%) of 392 study patients
admitted to the ICU who had an initial negative rectal sur-
veillance culture had one or more additional rectal cul-
tures performed (median, 1; range, 1 to 14). Of these ini-
tially VRE-negative patients, 74 (21%) of 352 were subse-
quently found to be colonized with VRE. One patient had
a positive urine culture for VRE 4 days after a negative
admission rectal swab; the remaining cases were discov-
ered by development of a positive rectal swab culture. The
median time to development of a positive VRE culture
FIGURE. Distribution of the study population. Percentages are in paren-
theses. ICU = intensive care unit; VRE = vancomycin-resistant
Enterococcus.
TABLE 1
DEMOGRAPHICS OF 519 PATIENTS ADMITTED TO THE INTENSIVE









Cancer 31   (6)
HIV infection 20   (4)
Diabetes mellitus 180 (35)
Baseline renal function
Normal 395 (76)
Chronic renal failure 71 (14)
Chronic renal failure with dialysis 53 (10)
Cirrhosis 33   (6)
Bone marrow transplant 28   (5)
Surgery in past 28 days 18   (4)





Antifungal 48   (9)
Processes of care
Chemotherapy 11   (2)
Corticosteroid use 176 (34)
Tracheostomy 56 (11)
Antacid use 52 (10)
H2 histamine antagonist 202 (39)
Sucralfate use 18   (4)
Vasopressor use 200 (39)
Enteral nutrition 233 (45)
Mechanical ventilation 342 (66)
Mean total CVC days (median) 5    (0)
 1 CVC inserted 244 (47)
Mean ventilator days (median) 6    (3)
Outcomes
Clostridium difficile diarrhea 31   (6)
VRE prevalence 127 (25)
Mean pre-ICU LOS, d (range) 5    (1–91)
Mortality 135 (26)
CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; HIV = human
immunodeficiency virus; ICU = intensive care unit; APACHE II = Acute Physiology and Chronic
Health Evaluation; CVC = central venous catheter; VRE = vancomycin-resistant Enterococcus;
LOS = length of stay.
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after ICU admission was 6 days (range, 2 to 36 days). Risk
factors for VRE acquisition in the ICU are listed in Table
4. Increased mean APACHE II score on ICU admission (P
= .002), sucralfate use (P = .003), vasopressor use (P =
.01), tracheostomy in the ICU (P = .02), and Clostridium
dif ficile diarrhea (P = .002) appeared to be associated with
becoming VRE culture positive; however, none of these
variables were significant after performing the Bonferroni
correction for multiple comparisons. The overall inci-
dence density of VRE acquisition was 27 cases per 1,000
patient-ICU days at risk. There was no significant increase
in the incidence density between the initial third and the
final two thirds of the study (data not shown).
DISCUSSION
This prospective cohort study of MICU patients
found a high prevalence of VRE colonization among
patients admitted to the ICU. Being a chronic dialysis
patient, having been admitted to the study hospital within
the 12 months prior to the current admission, and having
stayed in the hospital for 3 days or more prior to the ICU
admission were independently associated with being col-
onized with VRE on ICU admission. We also found a high
rate of becoming VRE culture positive within the ICU
despite the presence of an active surveillance culture pro-
gram.
The finding of an increased prevalence of VRE colo-
TABLE 2
COMPARISON OF PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT WHO WERE AND WERE NOT COLONIZED WITH VANCOMYCIN-
RESISTANT ENTEROCOCCUS
No VRE VRE Positive
(N = 392) (N = 127) AOR
Variable No. (%) No. (%) P (CI95)
‡
Mean age, y (range) 58 (16–103) 62 (21–102) .03
White 216 (55) 66 (52) .73
Male 192 (49) 62 (49) .98
CHF 80 (20) 24 (19) .71
COPD 97 (25) 34 (27) .65
Cancer 27   (7) 4   (3) .12
Chemotherapy 8   (2) 3   (2) .74
HIV infection 16   (4) 4   (3) .79
Diabetes mellitus 125 (32) 55 (43) .02
Baseline renal function
Normal 315 (80) 80 (63) Ref. Ref.
Chronic renal failure 49 (13) 22 (17) .05* 1.3 (0.7–2.3)
Chronic renal failure with dialysis 28   (7) 25 (20) < .001*,† 2.4 (1.2–4.5)
Cirrhosis 24   (6) 9   (7) .70
Corticosteroid use 129 (33) 47 (37) .40
Enteral nutrition 163 (42) 62 (49) .153
Bone marrow transplantation 16   (4) 12   (9) .02
Surgery in past 28 days 12   (3) 6   (5) .40
Tracheostomy 35   (9) 21 (17) .03
Barnes–Jewish Hospital admissions
in previous 12 mo
None 247 (63) 42 (33) Ref. Ref.
1–2 admissions 102 (26) 41 (32) .001*,† 2.3 (1.4–3.8)
> 2 admissions 43 (11) 44 (35) < .001*,† 6.5 (3.7–11.6)
Pre-ICU hospital LOS  3 d 96 (25) 65 (51) < .001† 3.6 (2.3–5.7)
Mean APACHE II score 22 24 .03
Pre-ICU antimicrobial use
Anti–gram-negative 97 (25) 63 (50) < .001†
Anti–gram-positive 99 (25) 61 (48) < .001†
Antianaerobic 42 (11) 37 (29) < .001†
Antifungal 22   (6) 25 (20) < .001†
CHF = congestive heart failure; ICU = intensive care unit; APACHE = Acute Physiology and Chronic Health Evaluation; HIV = human immunodeficiency virus; COPD = chronic obstructive pulmonary
disease; Ref. = reference group; LOS = length of stay; AOR = adjusted odds ratio; CI95 = 95% confidence interval; VRE = vancomycin-resistant Enterococcus.
*Obtained from univariate logistic regression.
†Significant after Bonferroni correction.
‡Other variables considered for inclusion in the final model: APACHE II score on admission, age, diabetes mellitus, bone marrow transplantation, pre-ICU antimicrobial use, and tracheostomy.
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nization among hemodialysis patients has been previous-
ly noted.15,16 Our rate of colonization (20%) is much high-
er than those of these prior studies, which focused on out-
patient hemodialysis subjects. We found that the risk of
being colonized with VRE on admission to the ICU
increased considerably when the patient had one or more
hospitalizations at our facility within the past year, or if the
patient had stayed in the hospital for 3 days or more prior
to ICU admission. These findings suggest that a signifi-
cant amount of nosocomial transmission of VRE may
occur in our institution, both in and out of the ICU.
Another potential explanation for this observation may be
that patients who are frequently admitted to acute care
facilities are also commonly admitted to skilled nursing
facilities, which are known reservoirs of VRE.17,18 We
were unable to consistently ascertain whether patients in
this study were transferred from a skilled nursing facility
or another hospital. Previous individual exposure to
antimicrobials, particularly vancomycin19,20 and
cephalosporins,4,10 has been associated with having a pos-
itive VRE culture. However, a meta-analysis of antecedent
vancomycin use and VRE colonization found no signifi-
cant association in studies controlling for pre-ICU length
of hospital stay.21 Additionally, the use of antibiotics with
anaerobic activity is associated with increased colony
counts of VRE and environmental dissemination among
VRE carriers.22 Therefore, global antibiotic exposure,
rather than individual antibiotic use, might be a better
predictor of VRE prevalence and incidence within a given
population. Because antibiotic use in this population was
highly correlated with prolonged pre-ICU length of stay
and problems with model overfitting when antibiotic days
were used in the model, we chose to include the length of
stay variable in our analyses.
Active surveillance cultures using rectal swab spec-
imens were performed only in the study ICU at
Barnes–Jewish Hospital. The policy for all other inpatient
units was that all clinical stool specimens sent to the
microbiology department for testing for C. dif ficile toxin
were also tested for the presence of VRE. If this culture or
other clinical specimens grew VRE, or if the patient was
known to be colonized with VRE from a previous admis-
sion, then he or she was placed in contact isolation, using
gowns and gloves. This testing strategy was similar to that
being employed at another Midwestern hospital.23 In that
hospital, the strategy yielded comparable results: specifi-
cally, 14% of the patients were colonized with VRE on
admission to the MICU and a pre-ICU length of hospital
stay of 3 or more days was strongly associated with being
VRE culture positive. That study, along with our results,
suggests that active surveillance cultures and contact pre-
cautions for VRE in a single hospital unit can have only a
limited impact on the prevalence of VRE in that unit, due
to unrecognized transmission occurring elsewhere in the
hospital where such control measures are not being used.
Patients who became VRE culture positive did so roughly
1 week after ICU admission. This finding suggests that
several patients had VRE fecal carriage at concentrations
below the level of detection of the admission rectal swab
culture, only to subsequently become positive for VRE
after antibiotic exposure in the ICU resulted in an
increase in enteric colony counts.
It is costly for institutions to perform active surveil-
lance of all ICU admissions. An alternative method of
screening would be to isolate and culture only patients
who had one or more independent risk factors for VRE
colonization. Previous studies have shown that selective
surveillance for MRSA among high-risk patients reduces
the transmission of that organism within an acute care set-
ting24,25 and is cost-effective.11 In our study, a strategy to
isolate and screen patients based on two readily available
criteria (admission to our hospital within the past year and
pre-ICU length of stay of 3 or more days during the cur-
rent admission) would detect VRE colonization with a sen-
sitivity of 93% and reduce the number of admission
screening tests needed by 39%. The clinical effectiveness
and cost-effectiveness of this approach for the control of
VRE infection needs to be tested.
We found an extremely high rate of VRE acquisition
among ICU patients (21%) and a relatively short median
time to acquisition of VRE (6 days). These findings are
similar to those from a study by Bonten et al.10 in which
15% of MICU patients were colonized with VRE on admis-
sion and 29% of susceptible patients became colonized
with VRE after a mean of 7.4 days. However, our acquisi-
tion rate was slightly higher than that obtained by
Ostrowsky et al., who found an acquisition rate of 13%
among surgical ICU patients.4 The risk factors that were
suggested on univariate analysis to be associated with
TABLE 3
SENSITIVITY AND SPECIFICITY OF A VARIABLE TO PREDICT
VANCOMYCIN-RESISTANT ENTEROCOCCUS COLONIZATION AMONG
ADMISSIONS TO THE INTENSIVE CARE UNIT
% of ICU
Variable Sensitivity Specificity Admissions
One predictor
variable present
A. Chronic renal 22% 93% 10
failure with dialysis
B. Pre-ICU 61% 76% 31
hospital LOS  3 d
C. Barnes–Jewish 78% 63% 44
Hospital admission
in previous 12 mo
Two of three predictor
variables present
A and B 69% 66% 41
A and C 81% 59% 48
B and C 93% 48% 61
Any predictor 94% 46% 62
variable present
ICU = intensive care unit; LOS = length of stay.
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VRE acquisition include markers of increased severity of
illness (ie, vasopressor use, high APACHE II score on
admission, and tracheotomy), sucralfate use, and C. dif fi-
cile diarrhea. C. dif ficile diarrhea has been associated
with VRE acquisition in previous studies.26 The higher
severity of illness among colonized patients suggests that
sicker patients who require increased contact with health-
care workers are at increased risk of acquiring VRE from
the hands of healthcare workers. Observations of staff
compliance with contact isolation procedures were not
made during this study. However, a previous study in this
unit found 78% compliance with glove use, but only 11% of
the staff adequately washed their hands after leaving an
isolated patient’s room.27 Because we could not record all
antibiotic use during the ICU stay, this variable could not
be analyzed as a potential risk factor for VRE acquisition.
TABLE 4
UNIVARIATE ANALYSIS OF RISK FACTORS ASSOCIATED WITH ACQUISITION OF VANCOMYCIN-RESISTANT ENTEROCOCCUS DURING INTENSIVE
CARE UNIT STAY
No VRE Acquired VRE
(N = 278) (N = 74)
Variable No. (%) No. (%) P
Patient characteristics on admission
Mean age, y (range) 58 (16–97) 58 (17–91) .94
White 158 (57) 34 (46) .10
Male 130 (47) 36 (49) .77
CHF 58 (21) 13 (18) .53
COPD 61 (22) 25 (34) .04
Cancer 16  (6) 6   (8) .43
Chemotherapy 7  (3) 1   (1) 1.0
HIV 8  (3) 6   (8) .09
Diabetes 84 (30) 28 (38) .21
Corticosteroids 89 (32) 30 (41) .17
Enteral nutrition 121 (44) 37 (50) .30
Cirrhosis 19   (7) 4   (5) .80
Baseline renal function
Normal 222 (80) 59 (80) Ref.
Chronic renal failure 35 (13) 9 (12) .93*
Chronic renal failure with dialysis 2  (8) 6   (8) .88*
Bone marrow transplantation 12  (4) 4   (5) .75
Surgery in past 28 days 9  (3) 1   (1) .70
Mean APACHE II score (range) 22  (6–47) 25  (10–43) .002
Processes of care
Antacid use 29 (10) 9 (12) .67
H2 histamine antagonist 117 (42) 27 (37) .38
Sucralfate use 6    (2) 7 (10) .003
Vasopressor use 94 (34) 37 (50) .01
 1 CVC inserted 126 (45) 42 (57) .09
Mean total CVC days (range) 4   (0–43) 5   (0–24) .65
Mechanical ventilation 183 (66) 57 (77) .07
Re-intubation 32 (12) 12 (16) .32
Tracheostomy > 48 h after ICU admittance 25   (9) 14 (19) .02
Mean total ventilator days (range) 6   (0–52) 10   (0–69) .04
ICU-related events
Hepatic failure 53 (19) 12 (16) .56
Acute respiratory failure 178 (64) 53 (72) .22
Acute CHF 42 (15) 17 (23) .12
Seizure or coma 18   (7) 2   (3) .27
Clostridium difficile diarrhea 9   (3) 10 (14) .002
VRE = vancomycin-resistant Enterococcus; ICU = intensive care unit; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; HIV = human immunodeficiency virus; APACHE
II = Acute Physiology and Chronic Health Evaluation; CVC = central venous catheter.
*Obtained from univariate logistic regression.
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Some limitations exist in our study. Because of lim-
ited resources, we could not include patients admitted for
less than 48 hours in our study. These patients could have
been an unrecognized reservoir for VRE transmission to
other patients. Molecular typing of VRE isolates was not
performed, so transmission patterns within the ICU could
not be ascertained. We were also unable to collect daily
data on VRE colonization pressure and antibiotic pres-
sure, which have been noted to be associated with VRE
transmission, during each individual ICU stay.10
Antimicrobial resistance is an increasing problem
among critically ill patients. Resistance results in the use
of more costly, broader-spectrum antimicrobials for
empiric therapy in the ICU. Better understanding of the
prevalence of colonization with resistant organisms
among newly admitted ICU patients and the identification
of risk factors for colonization in this patient population
could allow for the development of new strategies for con-
trol. However, these new strategies would need to be test-
ed to confirm both clinical effectiveness and cost-effec-
tiveness.
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